Trial Profile
A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Luspatercept (Primary)
- Indications Beta-thalassaemia
- Focus Registrational; Therapeutic Use
- Acronyms BELIEVE
- Sponsors Celgene Corporation
- 01 Feb 2024 Results assessing effect of Luspatercept in stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia published in the American Journal of Hematology
- 12 Dec 2023 Results of post hoc Subgroup Analysis (n=52) assessing Efficacy and Safety of Luspatercept in Patients with HbE/beta Thalassemia presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Jun 2023 Results assessing effect of long-term luspatercept treatment on BMD and T-scores of the hip and lumbar spine over week 48 presented at the 28th Congress of the European Haematology Association